Drug intelligence / Profile preview

ciprofol + sevoflurane

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous, Inhalation

Overview

Ciprofol + sevoflurane is a combination anesthetic regimen where ciprofol (HSK3486) is used for induction of anesthesia followed by sevoflurane for maintenance. Ciprofol is a novel intravenous anesthetic that functions as a positive allosteric modulator of GABA-A receptors, with 4-5 times the potency of propofol. Sevoflurane is an inhalational anesthetic used for maintenance after successful intubation. This combination provides stable hemodynamics, reduced injection pain compared to propofol-based regimens, and effective anesthesia for various surgical procedures.

Brand names: CipofolUltaneSevorane
Other names: HSK3486 + sevoflurane

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on ciprofol + sevoflurane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ciprofol + sevoflurane.

Explore the full profile